CEL-SCI Reports Third Consecutive Month of Record Patient Enrollment in '15 for Phase III Head, Neck Cancer Trial

CEL-SCI Corporation

today announced that in March it has enrolled 29 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). March marks the third consecutive month of record enrollment for CEL-SCI this year following January and February 2015. 406 patients have been enrolled in the Phase III study as of March 31, 2015. "The accelerating pace of enrollment in our trial is very good. We expect to see continued increases in monthly patient enrollment throughout the year as new clinical centers are added and as existing centers gain more experience with Multikine," stated CEL-SCI Chief Executive Officer Geert Kersten.